Corona Remedies Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹441 Cr +22.2% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
CR

Corona Remedies Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Corona Remedies Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹342Cr
+14.8% YoY
−5.3% QoQ
Net profit
₹41Cr
−8.9% YoY
−21.2% QoQ
Margin
24%
+1 pp YoY
+2 pp QoQ
Price₹2,143
Market cap₹12.8K Cr
P/E60.6

The short version

CORONA Remedies targets a consistent revenue growth of around 15% annually, outpacing the Indian Pharmaceutical Market (IPM). CORONA Remedies targets consistent mid-teen revenue growth (~15%) and high-teen PAT growth (~20%) annually.

From Corona Remedies Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • CORONA Remedies targets a consistent revenue growth of around 15% annually, outpacing the Indian Pharmaceutical Market (IPM).
  • PAT (Profit After Tax) growth expectation is high-teens to 20% annually.
  • Volume growth contributes approximately 5% to overall growth, supported by new product introductions.
  • The company plans to launch 8 to 10 new products yearly, primarily organically (95%), with a few acquisitions (5-7%).
  • Expansion includes entry into new therapies like infertility, rheumatology, and spine.
  • Growth is driven by chronic and semi-chronic segments, constituting around 70-72% of revenue.
  • Increasing market share through specialist and super-specialist prescribers is a key focus.

2 more points from Corona Remedies Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Corona Remedies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Recently capitalized a 600 kg manufacturing line, unlocking 40% capacity.
  • Planning to consider adding a new manufacturing block around FY'28-'29 to support future growth.
  • Currently, no immediate need to add new lines such as injectable or biosimilar lines; will evaluate at the appropriate time.
  • Maintain a balanced mix of 65% in-house manufacturing and 35% CDMO/CMO outsourcing.

2 more points from Corona Remedies Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Corona Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

From the discussion, the following points related to order flow and growth can be inferred: - CORONA Remedies is focusing on organic growth with 15% revenue growth guidance. - The company has recently launched and is launching new products including those from the Bayer portfolio, biosimilars, and GLP-1 injectable by March 2026. - The company is expanding capacities, including unlocking 40% capacity by the 600 kg manufacturing line.

2 more points from Corona Remedies Ltd's call on order book

Create a free account to keep reading this call

Corona Remedies Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Corona Remedies Ltd Q3 FY26 results — key figures

Corona Remedies Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue342298+14.8%361-5.3%
Operating profit (EBITDA)8369+20.3%78+6.4%
Operating margin24%23%+1 pp22%+2 pp
Profit before tax5558-5.2%70-21.4%
Net profit (PAT)4145-8.9%52-21.2%
EPS (₹)6.747.32-7.9%8.53-21%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹441 Cr, net profit ₹60 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Corona Remedies Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Corona Remedies Ltd Q3 FY26 results?

CORONA Remedies targets a consistent revenue growth of around 15% annually, outpacing the Indian Pharmaceutical Market (IPM). CORONA Remedies targets consistent mid-teen revenue growth (~15%) and high-teen PAT growth (~20%) annually.

What is Corona Remedies Ltd share price analysis?

Corona Remedies Ltd currently shows a neutral. The stock trades at a P/E of 60.6 with a market cap of ₹12,823 Cr. Investors should review the full earnings analysis for detailed insights.

Is Corona Remedies Ltd planning capital expenditure?

Recently capitalized a 600 kg manufacturing line, unlocking 40% capacity.

Keep Corona Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.